BIOVENTUS INC - A (BVS) Stock Fundamental Analysis

USA Nasdaq NASDAQ:BVS • US09075A1088

8.21 USD
+0.11 (+1.36%)
At close: Feb 5, 2026
8.21 USD
0 (0%)
After Hours: 2/5/2026, 8:12:22 PM
Fundamental Rating

5

Taking everything into account, BVS scores 5 out of 10 in our fundamental rating. BVS was compared to 186 industry peers in the Health Care Equipment & Supplies industry. BVS has a medium profitability rating, but doesn't score so well on its financial health evaluation. BVS is valued quite cheap, while showing a decent growth score. This is a good combination!


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • BVS had positive earnings in the past year.
  • In the past year BVS had a positive cash flow from operations.
  • In multiple years BVS reported negative net income over the last 5 years.
  • BVS had a positive operating cash flow in 4 of the past 5 years.
BVS Yearly Net Income VS EBIT VS OCF VS FCFBVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

  • With a decent Return On Assets value of 1.11%, BVS is doing good in the industry, outperforming 75.81% of the companies in the same industry.
  • The Return On Equity of BVS (4.71%) is better than 77.42% of its industry peers.
  • BVS's Return On Invested Capital of 6.62% is amongst the best of the industry. BVS outperforms 80.65% of its industry peers.
Industry RankSector Rank
ROA 1.11%
ROE 4.71%
ROIC 6.62%
ROA(3y)-11.81%
ROA(5y)-6.59%
ROE(3y)-54.27%
ROE(5y)-31.1%
ROIC(3y)N/A
ROIC(5y)N/A
BVS Yearly ROA, ROE, ROICBVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • With a decent Profit Margin value of 1.39%, BVS is doing good in the industry, outperforming 74.73% of the companies in the same industry.
  • With a decent Operating Margin value of 8.03%, BVS is doing good in the industry, outperforming 75.81% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BVS has declined.
  • BVS has a better Gross Margin (67.76%) than 73.66% of its industry peers.
  • BVS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.03%
PM (TTM) 1.39%
GM 67.76%
OM growth 3Y-2.88%
OM growth 5Y-14.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y-1.56%
BVS Yearly Profit, Operating, Gross MarginsBVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BVS is destroying value.
  • Compared to 1 year ago, BVS has more shares outstanding
  • Compared to 5 years ago, BVS has more shares outstanding
  • BVS has a better debt/assets ratio than last year.
BVS Yearly Shares OutstandingBVS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
BVS Yearly Total Debt VS Total AssetsBVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • BVS has an Altman-Z score of 1.28. This is a bad value and indicates that BVS is not financially healthy and even has some risk of bankruptcy.
  • BVS has a Altman-Z score (1.28) which is in line with its industry peers.
  • BVS has a debt to FCF ratio of 6.22. This is a slightly negative value and a sign of low solvency as BVS would need 6.22 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 6.22, BVS is in the better half of the industry, outperforming 76.34% of the companies in the same industry.
  • BVS has a Debt/Equity ratio of 1.93. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of BVS (1.93) is worse than 81.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.93
Debt/FCF 6.22
Altman-Z 1.28
ROIC/WACC0.6
WACC11.09%
BVS Yearly LT Debt VS Equity VS FCFBVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.74 indicates that BVS should not have too much problems paying its short term obligations.
  • BVS's Current ratio of 1.74 is on the low side compared to the rest of the industry. BVS is outperformed by 66.67% of its industry peers.
  • A Quick Ratio of 1.14 indicates that BVS should not have too much problems paying its short term obligations.
  • BVS has a Quick ratio of 1.14. This is in the lower half of the industry: BVS underperforms 70.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.14
BVS Yearly Current Assets VS Current LiabilitesBVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 51.28% over the past year.
  • The earnings per share for BVS have been decreasing by -16.93% on average. This is quite bad
  • Looking at the last year, BVS shows a small growth in Revenue. The Revenue has grown by 1.58% in the last year.
  • BVS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.01% yearly.
EPS 1Y (TTM)51.28%
EPS 3Y-16.93%
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)1.58%
Revenue growth 3Y9.98%
Revenue growth 5Y11.01%
Sales Q2Q%-0.23%

3.2 Future

  • BVS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.05% yearly.
  • Based on estimates for the next years, BVS will show a small growth in Revenue. The Revenue will grow by 4.58% on average per year.
EPS Next Y41.83%
EPS Next 2Y30.71%
EPS Next 3Y25.05%
EPS Next 5YN/A
Revenue Next Year0.33%
Revenue Next 2Y3.66%
Revenue Next 3Y4.58%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BVS Yearly Revenue VS EstimatesBVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
BVS Yearly EPS VS EstimatesBVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 1 1.5

8

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 13.92, BVS is valued correctly.
  • 90.86% of the companies in the same industry are more expensive than BVS, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 27.67, BVS is valued a bit cheaper.
  • Based on the Price/Forward Earnings ratio of 10.22, the valuation of BVS can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, BVS is valued cheaper than 95.16% of the companies in the same industry.
  • BVS is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.20, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 13.92
Fwd PE 10.22
BVS Price Earnings VS Forward Price EarningsBVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BVS is valued cheaply inside the industry as 90.32% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BVS indicates a rather cheap valuation: BVS is cheaper than 96.77% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 12.71
EV/EBITDA 10.43
BVS Per share dataBVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BVS's earnings are expected to grow with 25.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.33
PEG (5Y)N/A
EPS Next 2Y30.71%
EPS Next 3Y25.05%

0

5. Dividend

5.1 Amount

  • No dividends for BVS!.
Industry RankSector Rank
Dividend Yield 0%

BIOVENTUS INC - A

NASDAQ:BVS (2/5/2026, 8:12:22 PM)

After market: 8.21 0 (0%)

8.21

+0.11 (+1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04
Earnings (Next)03-09
Inst Owners74.45%
Inst Owner Change-1.49%
Ins Owners2.5%
Ins Owner Change0.31%
Market Cap679.46M
Revenue(TTM)563.83M
Net Income(TTM)7.82M
Analysts80
Price Target15.3 (86.36%)
Short Float %2.87%
Short Ratio6.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.08%
Min EPS beat(2)-0.99%
Max EPS beat(2)29.14%
EPS beat(4)3
Avg EPS beat(4)86.47%
Min EPS beat(4)-0.99%
Max EPS beat(4)239.51%
EPS beat(8)7
Avg EPS beat(8)133.13%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.3%
Min Revenue beat(2)-0.67%
Max Revenue beat(2)0.07%
Revenue beat(4)2
Avg Revenue beat(4)1.04%
Min Revenue beat(4)-0.67%
Max Revenue beat(4)4.79%
Revenue beat(8)6
Avg Revenue beat(8)4.08%
Revenue beat(12)9
Avg Revenue beat(12)2.76%
Revenue beat(16)10
Avg Revenue beat(16)1.33%
PT rev (1m)0%
PT rev (3m)2.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)3.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE 13.92
Fwd PE 10.22
P/S 1.21
P/FCF 12.71
P/OCF 12.13
P/B 4.09
P/tB N/A
EV/EBITDA 10.43
EPS(TTM)0.59
EY7.19%
EPS(NY)0.8
Fwd EY9.78%
FCF(TTM)0.65
FCFY7.87%
OCF(TTM)0.68
OCFY8.25%
SpS6.81
BVpS2.01
TBVpS-2.64
PEG (NY)0.33
PEG (5Y)N/A
Graham Number5.16
Profitability
Industry RankSector Rank
ROA 1.11%
ROE 4.71%
ROCE 8.38%
ROIC 6.62%
ROICexc 7.18%
ROICexgc 31.69%
OM 8.03%
PM (TTM) 1.39%
GM 67.76%
FCFM 9.48%
ROA(3y)-11.81%
ROA(5y)-6.59%
ROE(3y)-54.27%
ROE(5y)-31.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y44.62%
ROICexgc growth 5Y-8.7%
ROICexc growth 3Y36.86%
ROICexc growth 5Y-12.41%
OM growth 3Y-2.88%
OM growth 5Y-14.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y-1.56%
F-Score8
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 1.93
Debt/FCF 6.22
Debt/EBITDA 3.44
Cap/Depr 5.36%
Cap/Sales 0.45%
Interest Coverage 250
Cash Conversion 60.26%
Profit Quality 683.69%
Current Ratio 1.74
Quick Ratio 1.14
Altman-Z 1.28
F-Score8
WACC11.09%
ROIC/WACC0.6
Cap/Depr(3y)9.96%
Cap/Depr(5y)13.06%
Cap/Sales(3y)1.19%
Cap/Sales(5y)1.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.28%
EPS 3Y-16.93%
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y41.83%
EPS Next 2Y30.71%
EPS Next 3Y25.05%
EPS Next 5YN/A
Revenue 1Y (TTM)1.58%
Revenue growth 3Y9.98%
Revenue growth 5Y11.01%
Sales Q2Q%-0.23%
Revenue Next Year0.33%
Revenue Next 2Y3.66%
Revenue Next 3Y4.58%
Revenue Next 5YN/A
EBIT growth 1Y178.93%
EBIT growth 3Y6.82%
EBIT growth 5Y-5.11%
EBIT Next Year16.21%
EBIT Next 3Y12.72%
EBIT Next 5YN/A
FCF growth 1Y29806.1%
FCF growth 3Y34.24%
FCF growth 5Y-0.3%
OCF growth 1Y448.75%
OCF growth 3Y19.05%
OCF growth 5Y-0.96%

BIOVENTUS INC - A / BVS FAQ

Can you provide the ChartMill fundamental rating for BIOVENTUS INC - A?

ChartMill assigns a fundamental rating of 5 / 10 to BVS.


What is the valuation status for BVS stock?

ChartMill assigns a valuation rating of 8 / 10 to BIOVENTUS INC - A (BVS). This can be considered as Undervalued.


Can you provide the profitability details for BIOVENTUS INC - A?

BIOVENTUS INC - A (BVS) has a profitability rating of 5 / 10.


What is the valuation of BIOVENTUS INC - A based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BIOVENTUS INC - A (BVS) is 13.92 and the Price/Book (PB) ratio is 4.09.


What is the financial health of BIOVENTUS INC - A (BVS) stock?

The financial health rating of BIOVENTUS INC - A (BVS) is 3 / 10.